:m arim astat是一类作用于基质金属蛋白酶 (MMP)的全新的抗肿瘤药。研究发现基质金属蛋白酶能作用于细胞外基质 ,其过高的活性能破坏后者的正常生理作用 ,促进肿瘤的生长、浸润与转移。临床前和临床试验都发现作为基质金属蛋白酶抑制剂的 m arimastat能有效地抑制其活性 ,从而抑制肿瘤的生长、浸润与转移。同时该药还具有毒副作用小、病人耐受好等特点 ,使其在抗肿瘤方面具有良好的应用前景 : m arim astat is a new class of antineoplastic agents that act on matrix metalloproteinases (MMPs). The study found that matrix metalloproteinase can act on the extracellular matrix, its high activity can undermine the latter’s normal physiological role, and promote tumor growth, invasion and metastasis. Preclinical and clinical trials have found that marimastat, a matrix metalloproteinase inhibitor, can effectively inhibit its activity and thus inhibit tumor growth, invasion and metastasis. At the same time the drug also has small side effects, patient tolerance, etc., so that it has a good anti-tumor application prospects